1. Home
  2. PBM vs GLTO Comparison

PBM vs GLTO Comparison

Compare PBM & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBM
  • GLTO
  • Stock Information
  • Founded
  • PBM 1994
  • GLTO 2011
  • Country
  • PBM Canada
  • GLTO Denmark
  • Employees
  • PBM N/A
  • GLTO N/A
  • Industry
  • PBM
  • GLTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBM
  • GLTO Health Care
  • Exchange
  • PBM NYSE
  • GLTO Nasdaq
  • Market Cap
  • PBM 5.3M
  • GLTO 6.5M
  • IPO Year
  • PBM N/A
  • GLTO 2020
  • Fundamental
  • Price
  • PBM $1.26
  • GLTO $4.52
  • Analyst Decision
  • PBM
  • GLTO Buy
  • Analyst Count
  • PBM 0
  • GLTO 1
  • Target Price
  • PBM N/A
  • GLTO $10.00
  • AVG Volume (30 Days)
  • PBM 526.0K
  • GLTO 17.6K
  • Earning Date
  • PBM 02-02-2025
  • GLTO 03-07-2025
  • Dividend Yield
  • PBM N/A
  • GLTO N/A
  • EPS Growth
  • PBM N/A
  • GLTO N/A
  • EPS
  • PBM N/A
  • GLTO N/A
  • Revenue
  • PBM N/A
  • GLTO N/A
  • Revenue This Year
  • PBM N/A
  • GLTO N/A
  • Revenue Next Year
  • PBM N/A
  • GLTO N/A
  • P/E Ratio
  • PBM N/A
  • GLTO N/A
  • Revenue Growth
  • PBM N/A
  • GLTO N/A
  • 52 Week Low
  • PBM $1.21
  • GLTO $4.40
  • 52 Week High
  • PBM $323.25
  • GLTO $23.50
  • Technical
  • Relative Strength Index (RSI)
  • PBM 37.76
  • GLTO 40.56
  • Support Level
  • PBM $1.21
  • GLTO $4.50
  • Resistance Level
  • PBM $1.59
  • GLTO $5.25
  • Average True Range (ATR)
  • PBM 0.24
  • GLTO 0.34
  • MACD
  • PBM 0.03
  • GLTO -0.05
  • Stochastic Oscillator
  • PBM 17.53
  • GLTO 9.63

About PBM PSYENCE BIOMEDICAL LTD

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: